Type 1 diabetes is caused by insulin deficiency resulting from immune-mediated destruction of pancreatic beta cells. Its cause is multifactorial, with complex genetic factors and a strong influence of ...

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...

Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...

A Janus kinase (JAK) inhibitor helped preserve beta-cell function in people with recent-onset type 1 diabetes, the phase II BANDIT trial found. Meeting the study's primary endpoint, daily baricitinib ...

Please provide your email address to receive an email when new articles are posted on . Zimislecel is an investigational stem cell-derived islet therapy for type 1 diabetes. Ten of 12 participants no ...